Follow
Timothy A. Chan
Title
Cited by
Cited by
Year
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
NA Rizvi, MD Hellmann, A Snyder, P Kvistborg, V Makarov, JJ Havel, ...
Science 348 (6230), 124-128, 2015
70592015
Genetic basis for clinical response to CTLA-4 blockade in melanoma
A Snyder, V Makarov, T Merghoub, J Yuan, JM Zaretsky, A Desrichard, ...
New England Journal of Medicine 371 (23), 2189-2199, 2014
39952014
The immune landscape of cancer
V Thorsson, DL Gibbs, SD Brown, D Wolf, DS Bortone, THO Yang, ...
Immunity 48 (4), 812-830. e14, 2018
30992018
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
N McGranahan, AJS Furness, R Rosenthal, S Ramskov, R Lyngaa, ...
Science 351 (6280), 1463-1469, 2016
25182016
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ...
Nature genetics 51 (2), 202-206, 2019
22632019
Integrated genomic characterization of papillary thyroid carcinoma
N Agrawal, R Akbani, BA Aksoy, A Ally, H Arachchi, SL Asa, JT Auman, ...
Cell 159 (3), 676-690, 2014
20602014
IDH mutation impairs histone demethylation and results in a block to cell differentiation
C Lu, PS Ward, GS Kapoor, D Rohle, S Turcan, O Abdel-Wahab, ...
Nature 483 (7390), 474-478, 2012
19252012
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
S Turcan, D Rohle, A Goenka, LA Walsh, F Fang, E Yilmaz, C Campos, ...
Nature 483 (7390), 479-483, 2012
19132012
An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics
J Liu, T Lichtenberg, KA Hoadley, LM Poisson, AJ Lazar, AD Cherniack, ...
Cell 173 (2), 400-416. e11, 2018
17932018
Oncogenic signaling pathways in the cancer genome atlas
F Sanchez-Vega, M Mina, J Armenia, WK Chatila, A Luna, KC La, ...
Cell 173 (2), 321-337. e10, 2018
17922018
Comprehensive characterization of cancer driver genes and mutations
MH Bailey, C Tokheim, E Porta-Pardo, S Sengupta, D Bertrand, ...
Cell 173 (2), 371-385. e18, 2018
17122018
Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer
KA Hoadley, C Yau, T Hinoue, DM Wolf, AJ Lazar, E Drill, R Shen, ...
Cell 173 (2), 291-304. e6, 2018
15322018
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
JJ Havel, D Chowell, TA Chan
Nature Reviews Cancer 19 (3), 133-150, 2019
14862019
PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs
TC He, TA Chan, B Vogelstein, KW Kinzler
Cell 99 (3), 335-345, 1999
14821999
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
TA Chan, M Yarchoan, E Jaffee, C Swanton, SA Quezada, A Stenzinger, ...
Annals of Oncology 30 (1), 44-56, 2019
14152019
Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses
KB Chiappinelli, PL Strissel, A Desrichard, H Li, C Henke, B Akman, ...
Cell 162 (5), 974-986, 2015
13912015
Tumor and microenvironment evolution during immunotherapy with nivolumab
N Riaz, JJ Havel, V Makarov, A Desrichard, WJ Urba, JS Sims, FS Hodi, ...
Cell 171 (4), 934-949. e16, 2017
13102017
14-3-3σ is required to prevent mitotic catastrophe after DNA damage
TA Chan, H Hermeking, C Lengauer, KW Kinzler, B Vogelstein
Nature 401 (6753), 616-620, 1999
12661999
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells
D Rohle, J Popovici-Muller, N Palaskas, S Turcan, C Grommes, ...
Science 340 (6132), 626-630, 2013
11652013
CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy
W Wang, M Green, JE Choi, M Gijón, PD Kennedy, JK Johnson, P Liao, ...
Nature 569 (7755), 270-274, 2019
11172019
The system can't perform the operation now. Try again later.
Articles 1–20